MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Clinical trial NCT03697512 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03697512
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-27
- Primary completion
- 2027-06-15
- Enrollment
- 175
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.